Day 1 - Day 2 - Download Brochure
Tuesday, April 7
1:30 Chairperson’s Opening Remarks
1:40 Exploiting Kinase Polypharmacology in Cell Cycle Regulation via High-Content Imaging
Jeffrey Sutherland, Ph.D., Discovery Informatics, Eli Lilly and Company
Limitations of target-based drug discovery include the consequences of removing target proteins from their cellular context, wherein modifications or interactions with other proteins may play essential roles, and an inability to anticipate polypharmacology. This presentation focuses on drug discovery efforts at Lilly taking advantage of high content imaging methods coupled with informatics tools to collect and analyze data from disease relevant cellular systems and their potential to guide SAR.
2:10 Binding Modes of Fragment-Like Kinase Inhibitors
Keith Constantine, Ph.D., Bristol-Myers Squibb
Strategies for Observing and Interpreting Kinase-Inhibitor Nuclear Overhauser
Effects In support of kinase drug discovery efforts at Bristol Myers Squibb, we have developed and utilized methods for rapidly observing and interpreting nuclear Overhauser effects (NOEs) from kinase-inhibitor complexes. This presentation will illustrate the use of residue type-selective protonation and/or protein stabilization for observing kinase-inhibitor NOEs with adequate sensitivity, and how such data can greatly assist the structural modeling of these complexes. Our results include the detection of relatively large protein conformational changes in response to a relatively small inhibitor modifications, and the descrimination of multiple and single binding modes for fragment-like kinase inhibitors. The application of a pose scoring algorithm (NOE matching) to a kinase-inhibitor complex will also be described.
2:40 Title to be Announced
Peter A. Petillo, Ph.D., Senior Vice President, Dicephera Pharmaceuticals
3:10 Sponsored Presentation
3:25 Networking Refreshment Break in the Exhibit Hall
4:05 From HTS to Clinical Compound: Discovery of Potent and Exquisitely Selective C-Met Inhibitor PF-4217903
Jingrong Jean Cui, Ph.D., Associate Research Fellow, Research Chemistry, Pfizer, Inc.
PF-4217903 was a potent and exquisitely selective c-Met inhibitor currently in Phase I clinical trial for oncology application. This unique drug discovery story covered structure evaluation of a HTS Hit, identification of an exquisitely selective c-Met inhibitor binding mode, structure based drug design, and medicinal chemistry lead optimization on ADME,in vivo PK and toxicity properties.
4:35 Identification of Potent and Selective Inhibitors of Trk Kinases
Tao Wang, Ph.D., Principal Scientist, Cancer, AstraZeneca
The design, synthesis and biological evaluation of a series of potent Trk kinase inhibitors is reported. High-throughput screening identified a promising hit. Initial optimization of the series led to improvement of in vitro potency. Further optimization using two strategies resulted in significant improvement of physical properties.
5:05 Breakout Discussions with the Experts
Topic 1: discussing pre-clinical challenges
Moderator: Stephan K. Grant, PhD, Senior Director, Biochemistry and Primary Screening Oncology Research Unit Pfizer La Jolla Laboratories
Topic 2: Residence time - the new dimension for lead optimization
Moderator: Doris Hafenbradl, Ph.D., Executive VP, Screening & Proteins, Proteros
solutions for kinetic drug-target interaction studies
new technologies and methodsis slow always better?
In vitro and in vivo comparisons
Entropy and enthalpy – new parameters on the horizon?
Topic 3: Fragment-Based Drug Design
Moderator: Dr. Patrick Zarrinkar, Ph.D., VP of Technology Development, Ambit Bio
6:15 End of Day
For more information on this conference, contact :
Margit Eder, Ph.D., Conference Director
Cambridge Healthtech Institute
For Sponsor and Exhibit Information, contact:
Suzanne Carol, Business Development Manager
Cambridge Healthtech Institute